

Chronic Obstructive Pulmonary Disease, Asthma, and Risk of Type 2 Diabetes in Women

JAMAL S. RANA, MD¹
MURRAY A. MITTLEMAN, MD, DRPH^{1,2}
JAVED SHEIKH, MD³
FRANK B. HU, MD, PHD⁴
JOANN E. MANSON, MD, DRPH^{2,5,6}

GRAHAM A. COLDITZ, MD, DRPH^{2,5}
FRANK E. SPEIZER, MD⁵
R. GRAHAM BARR, MD, DRPH^{5,7}
CARLOS A. CAMARGO, JR., MD, DRPH^{2,5,8}

OBJECTIVE — Inflammation plays a key role in chronic obstructive pulmonary disease (COPD) and asthma. Increasing evidence points toward a role of inflammation in the pathogenesis of type 2 diabetes. We wanted to determine the relation of COPD and asthma with the development of type 2 diabetes.

RESEARCH DESIGN AND METHODS — The Nurses' Health Study is a prospective cohort study. From 1988–1996, 103,614 female nurses were asked biennially about a physician diagnosis of emphysema, chronic bronchitis, asthma, and diabetes.

RESULTS — During 8 years of follow-up, we documented a total of 2,959 new cases of type 2 diabetes. The risk of type 2 diabetes was significantly higher for patients with COPD than those without (multivariate relative risk 1.8, 95% CI 1.1–2.8). By contrast, the risk of type 2 diabetes among asthmatic patients was not increased (1.0, 0.8–1.2). The asthma results remained non-significant even when we evaluated diabetes risk by duration of asthma exposure.

CONCLUSIONS — Our findings suggest that COPD may be a risk factor for developing type 2 diabetes. Differences in the inflammation and cytokine profile between COPD and asthma might explain why COPD, but not asthma, is associated with increased risk of type 2 diabetes.

Diabetes Care 27:2478–2484, 2004

Chronic inflammation has emerged as a new risk factor for the development of type 2 diabetes (1–3). Increasing evidence now points toward a role of proinflammatory cytokines such as C-reactive protein (CRP), interleukin (IL)-6, and tumor necrosis factor (TNF)- α in the pathogenesis of insulin resistance

and type 2 diabetes (1–4). Due to the up-regulation of proinflammatory cytokines in both asthma and chronic obstructive pulmonary disease (COPD) (5,6), one might hypothesize that these chronic inflammatory diseases would increase risk for type 2 diabetes.

However, the pattern of inflammation

for asthma and COPD differs (7). The cellular infiltrate in asthma contains prominent numbers of eosinophils and type 2 helper (Th2) CD4 T-cells and associated cytokines (IL-4, -5, and -13) (5). By contrast, the cellular infiltrate in COPD is dominated by neutrophils, macrophages, and an increased numbers of lymphocytes thought to be type 1 helper (Th1) or CD8 T-cells (8), and the neutrophil-associated cytokines (TNF- α , IL-6, and IL-8) predominate (9). A recent report (10) from the Third National Health and Nutrition Examination Survey demonstrated that increasing severity of COPD was associated with increasing levels of CRP. Moreover, systemic inflammation in COPD is associated with increased muscle wasting and a continuous hypoxemic state due to destruction of lung tissue (11). Because of these inflammatory differences, the relationship of COPD or asthma with the development of another condition with an inflammatory component, such as type 2 diabetes, may vary.

We therefore evaluated the association between a history of physician-diagnosed COPD or asthma and incidence of type 2 diabetes among almost 100,000 participants in the Nurses' Health Study. We focused on potential differences in the diabetes risk conferred by COPD compared to that of asthma.

RESEARCH DESIGN AND METHODS

The Nurses' Health Study cohort was established in 1976 when 121,700 female registered nurses, aged 30–55 years and residing in 11 populous states, completed a mailed questionnaire about their medical history and lifestyle. Every 2 years, follow-up questionnaires have been sent to update information on potential risk factors and to identify newly diagnosed cases of cancer, coronary heart disease, diabetes, and other medical conditions. The baseline year for this analysis was 1988, when all participants were first asked about a physician diagnosis of emphysema, chronic bronchitis, and asthma. A total of

From the ¹Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts; the ²Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; the ³Division of Allergy and Inflammation, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts; the ⁴Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts; the ⁵Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; the ⁶Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; the ⁷Division of General Medicine, Department of Medicine, Columbia-Presbyterian Medical Center, New York, New York; and the ⁸Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Address correspondence and reprint requests to Dr. Camargo, Channing Laboratory, 181 Longwood Ave., Boston, MA 02115. E-mail: ccamargo@partners.org.

Received for publication 18 February 2004 and accepted in revised form 14 July 2004.

Abbreviations: COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; IL, interleukin; Th1, type 1 helper; Th2, type 2 helper; TNF, tumor necrosis factor.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2004 by the American Diabetes Association.

103,614 participants answered the supplementary questionnaire for asthma and COPD. For this analysis, we excluded women with type 1 diabetes, women classified as having only gestational diabetes, and those who had preexisting type 2 diabetes before 1988. We also excluded participants that lacked diabetes confirmation and were missing date of birth. Therefore, our baseline cohort for incident type 2 diabetes between 1988 and 1996 included 97,618 women.

There were a total of 5,986 participants with respiratory disease consistent with a diagnosis of asthma, COPD, or components of COPD, but not meeting the diagnostic criteria. Of these, 1,715 had COPD, but the date of onset was not available for 373, leaving 1,342 participants for inclusion in the study. Thus the COPD cohort included 97,245 participants: 1,342 with COPD and 95,903 free of COPD.

For the analyses of asthma, we excluded subjects with COPD ($n = 1,715$) and also those participants who had components of COPD but did not meet the diagnostic criteria ($n = 1,371$) from the baseline cohort. Date of onset of asthma was missing in 21 patients, leaving 2,879 participants with asthma for inclusion in the study. Thus the asthma cohort included 94,511 participants: 2,879 with asthma and 91,632 free of asthma.

At baseline, participants provided data on demographic, lifestyle, and biological factors, including age, race, current weight and height, smoking status, physical activity, dietary intake, and comorbid conditions. Participants also were asked if they had recently undergone a health screening examination or if they currently used any nutritional supplements. The participants contributed person-time until the end of follow-up or the time of type 2 diabetes diagnosis.

Ascertainment of respiratory disease

From 1988 to 1996, all participants were asked biennially about a physician diagnosis of emphysema, chronic bronchitis, and asthma. A supplementary questionnaire was sent in 1998 to all living nurses who reported a physician diagnosis of emphysema, chronic bronchitis, or asthma through 1996. This supplemental questionnaire requested information confirming a physician diagnosis of emphysema, chronic bronchitis, COPD, or asthma; dates of symptom onset and di-

agnosis; tests performed to confirm the diagnosis; and symptoms consistent with a diagnosis of chronic bronchitis (i.e., ≥ 2 months of productive cough for > 2 years).

The supplemental questionnaires also included items on recent medication use, respiratory symptoms, health care utilization (hospital visits, emergency department visits, and urgent office visits), and results of spirometry in the preceding year. The questionnaire-based definitions of COPD and asthma have been validated in prior publications (12,13).

Cases of COPD

The contemporary clinical definition of COPD was used: a diagnosis of COPD, emphysema, or chronic bronchitis with evidence of airflow obstruction that is not fully reversible (14). Definitions were established independent of smoking status. Since COPD is rarely diagnosed before age 35 years (14), cases were excluded if the reported age at COPD diagnosis was ≤ 35 years. Of the participants with COPD who were included in the study, 605 (45%) had some asthmatic component.

Cases of asthma

Using information from supplementary questionnaires and the special mailing to all asthmatic (and COPD) participants in 1998, each participant reporting asthma was categorized using two case definitions. Case definition 1 required both of the following: 1) reiterated on second questionnaire that a physician had diagnosed the subject as having asthma and 2) reported using an asthma medication (e.g., inhaled steroids, oral or intravenous steroids, theophylline, cromolyn or nedocromil, leukotriene modifiers, and salmeterol) since diagnosis. To meet case definition 2, participants had to fulfill the criteria of case definition 1 and report use of a prescribed long-term preventive medication (e.g., inhaled steroids) in the past year.

Ascertainment of type 2 diabetes

The outcome in this analysis was newly diagnosed type 2 diabetes between 1988 and 1996. We mailed a supplementary questionnaire regarding symptoms, diagnostic tests, and hyperglycemic treatments to all women who reported a diagnosis of diabetes on any biennial follow-up questionnaire. The diagnosis of diabetes was established when at least one

of the following criteria was reported on the supplementary questionnaire: 1) one or more classic symptom (excessive thirst, polyuria, weight loss, hunger, or coma) plus a fasting plasma glucose concentration of ≥ 140 mg/dl (7.8 mmol/l) or a random plasma glucose concentration of ≥ 200 mg/dl (11.1 mmol/l), 2) at least two elevated plasma glucose concentrations on different occasions (fasting, 140 mg/dl [7.8 mmol/l]; random, 200 mg/dl [11.1 mmol/l]; or random, 200 mg/dl [11.1 mmol/l] after at least 2 h of oral glucose tolerance testing) in the absence of symptoms, or 3) treatment with hypoglycemic medication (insulin or oral hypoglycemic agents). The diagnostic criteria for type 2 diabetes were changed in 1997 (15). However, we used the criteria proposed by the National Diabetes Data Group (16) because all of our case subjects were diagnosed before June 1996. The questionnaire-based definition of type 2 diabetes has been validated in a sample by medical record review (17).

Statistical analysis

Person-time for each participant was calculated from the date of return of the 1988 questionnaires to the date of confirmed type 2 diabetes between 1988 and 1996. Exposure status was updated every 2 years. We calculated rates of incident type 2 diabetes for women with prior COPD or asthma by dividing the number of incident cases by the number of person-years of follow-up contributed by women with COPD or asthma, respectively. The relative risk (RR) was computed as the rate among women with prior COPD or asthma divided by the rate among women without COPD or asthma, with adjustment for 5-year age categories. Risk of type 2 diabetes also was calculated for different durations of asthma (i.e., years since first diagnosis of asthma, with categories of < 10 , 10–20, and > 20 years). A test for trend across the categories of asthma duration was calculated by treating the categories as an ordinal variable in a proportional hazards model. Duration of COPD was not evaluated because it is a more slowly progressive disease and because, by the time of diagnosis, the patient may already have had the disease for unknown and variable amounts of time (18).

Multivariate Cox regression models were used to control for potential confounding by other risk factors for type 2

Table 1—Baseline characteristics of the 97,245 participants of the Nurses' Health Study in 1988

	COPD	No COPD	
		Asthma	No asthma*
<i>n</i>	1,342	2,879	93,024
Age (years)	58 ± 7	52 ± 7	54 ± 7
Race (%)			
White	93	92	87
Non-white	3	5	5
Missing	4	3	8
BMI (kg/m ²)	24.1 (21.6–27.3)	25.5 (22.8–29.2)	24.4 (22.1–27.5)
Family history of diabetes (%)	24	20	20
Hypertension (%)	19	20	16
Hormone replacement therapy (%)			
Premenopausal	24	29	29
Current user of estrogen only	9	12	8
Current user of estrogen and progesterone	6	7	5
Missing	20	17	20
Activity level (METs/week)	12 ± 18	14 ± 17	16 ± 22
Smoking status (%)			
Never smoker	16	48	44
Past smoker	31	41	36
Current light smoker (<25 cigarettes/day)	28	8	14
Current heavy smoker (≥25 cigarettes/day)	25	3	6
Pack-years	50 (37–67)	20 (8–35)	25 (12–43)
Daily alcohol intake (gm/day)	9 ± 14	6 ± 10	7 ± 10
Cereal fiber intake (gm/day)	4 ± 3	5 ± 3	5 ± 3
Trans fat intake (gm/day)	3 ± 1	3 ± 1	3 ± 1
Glycemic load index	10,923 ± 4,183	11,129 ± 4,118	11,044 ± 4,094
Polyunsaturated-to-saturated fat ratio	0.5 ± 0.2	0.5 ± 0.2	0.5 ± 0.2

Data are means ±SD or median (interquartile range), unless noted otherwise. *Includes 1,371 participants with a component of COPD not reaching diagnostic criteria and 21 subjects with asthma but without date of onset. MET, metabolic equivalent.

diabetes. The multivariate model adjusted age (in 5-year categories), time periods (in four categories), BMI (in seven categories), family history of diabetes, menopausal status, use of postmenopausal hormone therapy, weekly frequency of moderate-to-vigorous exercise (<0.5, 0.5–3.9, 4.0–6.9, or ≥7.0 h), smoking status (never smoked, former smoker, current smoker [<25 cigarettes/day] or current smoker [≥ 25 cigarettes/day]), daily alcohol intake, and a dietary score variable. Our choice of ≥ 25 cigarettes/day as a cut point was based on previously published data (19) from the Nurses' Health Study that showed that there was a 1.42-fold increased risk of diabetes associated with smoking ≥ 25 cigarettes per day. RR estimates were much lower and not statistically significant for lower levels of smoking, although the overall test for trend suggested a dose-response relationship.

The dietary score variable included information on dietary predictors of type

2 diabetes (20), including cereal fiber, trans fat, glycemic load, and the ratio of polyunsaturated to saturated fat. These data were derived from a 120-item, semi-quantitative, food frequency questionnaire. Each woman was assigned a score of each nutrient on the basis of quintiles of intake (a higher score represented a lower risk), and then the four scores were summed and the total score categorized into quintiles.

RESULTS— Table 1 shows the general characteristics of our cohort of 97,245 women. In 1988, the mean age of the participants was 54 years. The median BMI of our participants was 25.4 kg/m², and 34% were overweight or obese (BMI ≥ 25.0 kg/m²). Approximately 20% of the participants had a family history of diabetes, and 44% of the women were never smokers.

During 8 years of follow-up, we documented 2,959 new cases of type 2 diabetes in the COPD cohort, with 19 cases

of incident type 2 diabetes among the participants who had COPD. In the asthma cohort, we documented 2,827 new cases of type 2 diabetes, with 69 cases among the participants who had asthma. We calculated the age-, BMI-, and fully adjusted RRs of type 2 diabetes for participants with COPD or asthma compared with participants who did not have COPD or asthma, respectively (Table 2).

The age-adjusted risk of type 2 diabetes was higher for patients with COPD than those without (RR 1.8). After adjusting for potential confounders, the RR of diabetes for patients with COPD did not change (RR 1.8). In order to further control for potential confounding, we also ran an expanded model adjusting for potential confounding factors including age (in 5-year categories), time periods (in four categories), BMI (in seven categories), family history of diabetes, menopausal status, use of postmenopausal hormone therapy, weekly frequency of moderate-to-vigorous exercise (<0.5,

Table 2—Risk of type 2 diabetes from 1988 to 1996 according to COPD or asthma status

	Person-years	Incident diabetes	Age-adjusted RR (95% CI)	Age- and BMI-adjusted RR (95% CI)	Multivariate RR (95% CI)*
COPD cohort (n = 97,245)					
No COPD	726,840	2,940	1.0 (reference)	1.0 (reference)	1.0 (reference)
COPD	2,505	19	1.8 (1.1–2.8)	1.9 (1.2–3.0)	1.8 (1.1–2.8)
Asthma cohort (n = 94,511)					
No asthma	693,066	2,758	1.0 (reference)	1.0 (reference)	1.0 (reference)
Asthma	15,389	69	1.1 (0.9–1.5)	0.9 (0.7–1.2)	1.0 (0.8–1.2)

*Adjusted for age, BMI (in four categories), sedentary (weekly frequency of moderate-to-vigorous exercise <0.5 h), smoking status (never smoked, former smoker, current smoker [<25 cigarettes/day], or current smoker [≥ 25 cigarettes/day]), daily alcohol intake, and a dietary score variable.

0.5–3.9, 4.0–6.9, or ≥ 7.0 h), smoking status (never smoked, former smoker, current smoker [<25 cigarettes/day], or current smoker [≥ 25 cigarettes/day]), daily alcohol intake, and a dietary score variable. The results of this expanded model were similar (RR 1.8, 95% CI 1.1–2.8) to our primary results.

By contrast, the age-adjusted risk of diabetes was not significantly higher for patients with asthma than for those without (RR 1.1). Furthermore, after adjusting for potential confounders, the RR of type 2 diabetes for asthmatic patients was null (RR 1.0, 95% CI 0.8–1.2). Additional variables, as listed above, were included in an expanded model to further adjust for potential confounding, and the asthma result did not change (1.0, 0.8–1.2). To further explore the relation of asthma to diabetes risk, we examined whether the duration of asthma exposure was associated with the risk of developing type 2 diabetes. Compared with women without asthma, those with asthma for <10 , 10–20, and >20 years showed no significant association with incidence of diabetes (hazard ratios 0.6, 1.2, and 1.1, respectively).

To explore the effect of smoking on the association between COPD and asthma and risk of diabetes, we performed stratified analyses according to smoking status (Table 3). Although there was limited statistical power, there was a trend in never-smoker COPD patients for higher risk of type 2 diabetes (RR 1.4, 95% CI 0.46–4.5). There was no association between asthma (0.98, 0.69–1.38) and risk of diabetes. When we considered all smokers (past and current), the risk of diabetes remained higher in COPD patients (2.0, 1.2–3.2) when compared with asthma patients (1.01, 0.72–1.4). In a

sensitivity analysis, we also controlled for physician visits, and this factor did not alter our results (data not shown).

To address the possibility that surveillance may have varied according to COPD, we performed an analysis restricted to case subjects reporting at least one symptom of diabetes at diagnosis ($n = 1,554$, 52% of all case subjects). Results from this subgroup were not appreciably different from those for the entire cohort (RR 1.8, 95% CI 1.0–3.4). For asthma, the results also did not change ($n = 1,532$, 54% of all case subjects; RR 1.1, 95% CI 0.8–1.6).

In a separate analysis, we examined the potential differences in oral steroid use among women with COPD compared with women with asthma. On a question about usual medications between 1992 and 1994, oral steroids were reported by 9% of participants with COPD and 9% of participants with asthma ($P = 0.81$). Similarly, use of oral steroids “in the past year” was asked on the 1998 supplementary questionnaire and yielded values of 30% among women with COPD and 32% among women with asthma ($P = 0.27$).

CONCLUSIONS— In this prospective cohort study involving almost 100,000 women, we found that subjects with COPD had a statistically significant, increased risk of developing type 2 diabetes that persisted after multivariate adjustment for potential confounders. By contrast, such an association was not found among women with asthma. Glucose metabolism has not been studied extensively in COPD patients, and the available studies are inconclusive, perhaps due to differences in BMI and the hypoxemic state of this patient population (21–24). Our prospective study ex-

tends these earlier physiologic observations. Some studies have suggested that a reduced lung function could be a risk factor for the development of insulin resistance or diabetes (25–27). However, these studies only focused on impaired lung function (25,26) or forced vital capacity (27) and did not look into any association between physician-diagnosed COPD or asthma and risk of developing diabetes.

Although both asthma and COPD are chronic inflammatory conditions, we found no significant association between asthma and risk of type 2 diabetes. This could be due to differences in the type of inflammation in asthma versus COPD. The cellular infiltrate in asthma contains prominent numbers of eosinophils and Th2 cells (5). By contrast, the cellular infiltrate of COPD is dominated by neutrophils, macrophages, and Th1 cells (8), with associated cytokines such as TNF- α , IL-6, and IL-8 (9), which are also believed (28) to play a major role in the development of type 2 diabetes.

There are a number of ways in which COPD might lead to the development of type 2 diabetes. Inflammatory markers that are increased in patients with type 2 diabetes have been observed to be up-regulated in patients with COPD (9), suggesting that inflammation may be the common link. Elevated levels of CRP, IL-6, and TNF- α have been shown (1–4,29,30) to predict the development of the insulin resistance syndrome and type 2 diabetes, supporting a role for inflammation in the pathogenesis of diabetes.

The chronic state of inflammation in COPD patients is believed to shift the metabolism of the patients toward net protein catabolism, in turn increasing the resting energy expenditure (31). As a re-

Table 3—Risk of type 2 diabetes associated with COPD or asthma stratified by smoking status

	COPD		Asthma	
	n (%)	RR (95% CI)	n (%)	RR (95% CI)
All patients	1,342 (100)	1.8 (1.1–2.8)	2,879 (100)	1.0 (0.8–1.2)
Never smokers	215 (16)	1.4 (0.46–4.5)	1,382 (48)	0.98 (0.69–1.4)
Past smokers	416 (31)	2.2 (1.1–4.4)	1,180 (41)	1.05 (0.73–1.5)
Current smokers	711 (53)	1.7 (0.84–3.4)	317 (11)	0.79 (0.32–1.9)
All smokers	1,127 (84)	2.0 (1.2–3.2)	1,497 (52)	1.01 (0.72–1.4)

*Adjusted for age, BMI (in four categories), sedentary (weekly frequency of moderate-to-vigorous exercise <0.5 h), smoking status (never smoked, former smoker, current smoker [<25 cigarettes/day], or current smoker [≥ 25 cigarettes/day]), daily alcohol intake, and a dietary score variable.

sult, the fat-free mass of such patients is depleted (32–34), which is accompanied by an increase in systemic markers of inflammation (35,36). Other studies have also shown a link between systemic inflammation and skeletal muscle loss in COPD, even when weight loss is not apparent (37,38). Circulating TNF- α levels have been found to be elevated in cachectic COPD patients with chronic hypoxemia, a potential stimulus for activation of the proinflammatory cytokine system (39) in such patients. TNF- α , a central inflammatory mediator in the process of muscle wasting, promotes cachexia by reducing peripheral insulin action (30,40). Muscle loss and decreased fat oxidative capacity, along with low physical activity, lead to further muscle loss and fat gain. Fat gain in turn elevates circulating TNF- α , escalating insulin resistance and muscle loss.

Oxidative stress as seen in patients with COPD results in injury to the air-space epithelium, increased influx of neutrophils into the lungs, and activation of transcription factors, including nuclear factor- κ B, which switches on the genes for TNF- α , IL-8, and other inflammatory mediators (6,41,42). Such oxidative stress has been implicated in insulin resistance (43). Reactive oxygen species interfere with insulin signaling at various levels and are able to inhibit the translocation of GLUT4 in the plasma membrane, leading to insulin resistance (43). Moreover, an increase in insulin or glucose levels further increases reactive oxygen species production and oxidative stress, impairing both insulin action and secretion and accelerating the progression to overt type 2 diabetes.

The current study has some potential limitations. Our subjects included only women, the vast majority of whom were

Caucasian and had a similar socioeconomic status. Although the homogeneity in the sample would reduce confounding, it may also reduce the generalizability of our findings. Currently, we have no reason to suspect that men or non-Caucasians would differ in terms of the effects of COPD on diabetes. Future studies to evaluate this association in other populations would be informative. Women in our cohort who did not report diabetes were not uniformly screened for glucose intolerance. This may have misclassified some participants with unrecognized diabetes. Our epidemiologic definition of asthma and COPD also may have resulted in some misclassification of participants. There also might have been some misclassification of other covariates, and we cannot exclude a component of uncontrolled or residual confounding. We did, however, adjust for the major risk factors for diabetes (20).

We cannot rule out the possibility of that some or all of the effects of COPD on the risk of diabetes incidence that we observed was a result of residual confounding by cigarette smoking. In our analyses, we attempted to control for smoking in the multivariate models and through stratified analyses, dividing the population into four categories. Interestingly, we observed a 40% higher risk among subjects with COPD who reported being lifelong nonsmokers, although this finding did not reach statistical significance.

Our observation that 16% of the COPD patients reported being lifelong nonsmokers is consistent with prior epidemiological studies (44) that have reported that 5–12% of patients with prevalent COPD report having never smoked. Whether this reflects reporting

bias, the effects of second-hand smoke, or other exposures is unknown.

Another potential limitation is that the higher risk of type 2 diabetes among individuals with COPD may have been mediated, at least in part, by the use of systemic corticosteroids (45). We did not have data on the dosage or frequency of steroid use, so we were unable to control for it. The risk of developing corticosteroid-induced diabetes has only been seen with the use of systemic steroids (46,47), whereas there is no evidence for an association with the use of inhaled corticosteroids (47). In our cohort, at two different time points, there was no significant difference in the use of oral steroids between participants with asthma and COPD. If corticosteroid use was responsible for the development of type 2 diabetes, we would have expected to see a similar increased risk of type 2 diabetes among subjects with asthma. There remains a potential for detection bias as an explanation for these findings (e.g., adults with the diagnosis of COPD or asthma were more likely to be screened for diabetes). If that were the case, however, we would have expected to see similar increases in the diagnosis of diabetes for both the COPD and asthma groups.

In summary, our findings suggest that COPD but not asthma may be associated with a higher risk of developing type 2 diabetes. Further prospective studies are needed to test this hypothesis and to examine cytokine profiles (both Th1 and Th2) in COPD or asthmatic patients who go on to develop type 2 diabetes. Moreover, future prospective studies might examine whether COPD or asthma are associated with increased risk of other diseases with an inflammatory component, such as atherosclerosis.

Acknowledgments—This work was supported by Grants T32 HL07374, T32 HL07427, R01 HL63841, R01 DK58845, and R01 CA87969 from the National Institutes of Health (Bethesda, MD).

We are indebted to Catherine Wentowski for her untiring contributions toward data management and statistical analysis for this study. The authors also thank the participants in the Nurses' Health Study for their ongoing contributions and Gary Chase, Karen Corsano, Maureen Ireland-Johnston, and Barbara Egan for their invaluable assistance in implementing the study.

References

- Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. *Diabetes* 51:1131–1137, 2002
- Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* 286:327–334, 2001
- Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. *Diabetes* 52:812–817, 2003
- Hu FB, Meigs JB, Li TY, Rifai N, Manson JE: Inflammatory markers and risk of developing type 2 diabetes in women. *Diabetes* 53:693–700, 2004
- Renauld JC: New insights into the role of cytokines in asthma. *J Clin Pathol* 54:577–589, 2001
- Barnes PJ: Chronic obstructive pulmonary disease. *N Engl J Med* 343:269–280, 2000
- Barnes PJ: Mechanisms in COPD: differences from asthma. *Chest* 117 (Suppl. 2): 10S–14S, 2000
- Majori M, Corradi M, Caminati A, Cacciani G, Bertacco S, Pesci A: Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 103:458–462, 1999
- Chung KF: Cytokines in chronic obstructive pulmonary disease. *Eur Respir J Suppl* 34:50S–59S, 2001
- Mannino DM, Ford ES, Redd SC: Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. *Am J Med* 114:758–762, 2003
- Creutzberg EC, Casaburi R: Endocrinological disturbances in chronic obstructive pulmonary disease. *Eur Respir J* 22 (Suppl. 46):76S–80S, 2004
- Barr RG, Herbstman J, Speizer FE, Camargo CA Jr: Validation of self-reported chronic obstructive pulmonary disease in a cohort study of nurses. *Am J Epidemiol* 155:965–971, 2002
- Camargo CA Jr, Weiss ST, Zhang S, Willett WC, Speizer FE: Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. *Arch Intern Med* 159:2582–2588, 1999
- Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. *Respir Care* 46:798–825, 2001
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 20:1183–1197, 1997
- National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 28:1039–1057, 1979
- Manson JE, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, Krolewski AS, Rosner B, Hennekens CH, Speizer FE: Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. *Lancet* 338:774–778, 1991
- Anto JM, Vermeire P, Vestbo J, Sunyer J: Epidemiology of chronic obstructive pulmonary disease. *Eur Respir J* 17:982–994, 2001
- Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Hennekens CH, Speizer FE: Cigarette smoking and the risk of diabetes in women. *Am J Public Health* 83:211–214, 1993
- Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N Engl J Med* 345:790–797, 2001
- Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC: Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. *Diabetes Care* 17:961–969, 1994
- Hjalmarson A, Aasebo U, Birkeland K, Sager G, Jorde R: Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. *Diabetes Metab* 22:37–42, 1996
- Jakobsson P, Jorfeldt L, von Schenck H: Fat metabolism and its response to infusion of insulin and glucose in patients with advanced chronic obstructive pulmonary disease. *Clin Physiol* 15:319–329, 1995
- Jakobsson P, Jorfeldt L, von Schenck H: Insulin resistance is not exhibited by advanced chronic obstructive pulmonary disease patients. *Clin Physiol* 15:547–555, 1995
- Lazarus R, Sparrow D, Weiss ST: Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the Normative Aging Study. *Eur Respir J* 12:641–645, 1998
- Engstrom G, Janzon L: Risk of developing diabetes is inversely related to lung function: a population-based cohort study. *Diabet Med* 19:167–170, 2002
- Engstrom G, Hedblad B, Nilsson P, Wollmer P, Berglund G, Janzon L: Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. *J Intern Med* 253:574–581, 2003
- Grimble RF: Inflammatory status and insulin resistance. *Curr Opin Clin Nutr Metab Care* 5:551–559, 2002
- Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. *Arch Intern Med* 163:93–99, 2003
- Hotamisligil GS: The role of TNF α and TNF receptors in obesity and insulin resistance. *J Intern Med* 245:621–625, 1999
- Wouters EF: Chronic obstructive pulmonary disease. 5. Systemic effects of COPD. *Thorax* 57:1067–1070, 2002
- Congleton J: The pulmonary cachexia syndrome: aspects of energy balance. *Proc Nutr Soc* 58:321–328, 1999
- Schols AM: Nutritional and metabolic modulation in chronic obstructive pulmonary disease management. *Eur Respir J Suppl* 46:81S–86S, 2003
- Mador MJ: Muscle mass, not body weight, predicts outcome in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 166:787–789, 2002
- Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF: Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. *Thorax* 51:819–824, 1996
- Vermeeren MA, Schols AM, Wouters EF: Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. *Eur Respir J* 10:2264–2269, 1997
- Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DJ: Inflammatory response and body composition in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 164:1414–1418, 2001
- Pitsiou G, Kyriazis G, Hatzizisi O, Argyropoulou P, Mavrofridis E, Patakas D: Tumor necrosis factor- α serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. *Respir Med* 96:594–598, 2002
- Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki H, Kato S, Tomoike H: The relationship between chronic hypoxemia and activation of the tumor necrosis factor- α system in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 161:1179–1184, 2000
- Hotamisligil GS, Murray DL, Choy LN,

- Spiegelman BM: Tumor necrosis factor alpha inhibits signaling from the insulin receptor. *Proc Natl Acad Sci U S A* 91:4854–4858, 1994
41. Rahman I: Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. *J Biochem Mol Biol* 36:95–109, 2003
42. Rahman I, Gilmour PS, Jimenez LA, MacNee W: Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. *Mol Cell Biochem* 234–235:239–248, 2002
43. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L: The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. *Diabetes Metab Res Rev* 17:189–212, 2001
44. Coultas DB, Mapel D, Gagnon R, Lydick E: The health impact of undiagnosed airflow obstruction in a national sample of United States adults. *Am J Respir Crit Care Med* 164:372–377, 2001
45. Delaunay F, Khan A, Cintra A, Davani B, Ling ZC, Andersson A, Ostenson CG, Gustafsson J, Efendic S, Okret S: Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. *J Clin Invest* 100:2094–2098, 1997
46. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J: Glucocorticoids and the risk for initiation of hypoglycemic therapy. *Arch Intern Med* 154:97–101, 1994
47. Blackburn D, Hux J, Mamdani M: Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. *J Gen Intern Med* 17:717–720, 2002